Pre-diagnostic body mass index in relation to hormone receptor positive versus hormone receptor negative breast cancer incidence and mortality

Principal Investigator

Name
Omar Abdel-Rahman

Degrees
MD

Institution
Avicenna Oncology center

Position Title
Consultant and scientific director

Email
omar.abdelrhman@med.asu.edu.eg

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-432

Initial CDAS Request Approval
Dec 28, 2018

Title
Pre-diagnostic body mass index in relation to hormone receptor positive versus hormone receptor negative breast cancer incidence and mortality

Summary
Numerous studies have suggested a higher risk of breast cancer among patients with higher pre-diagnostic body mass index (BMI). However, little studies paid attention to the differential impact of BMI on hormone receptor positive versus hormone receptor negative breast cancer. Moreover, few studies evaluated the impact of BMI trajectory on breast cancer risk.

Aims

1. To evaluate the impact of pre-diagnostic BMI and BMI trajectory on breast cancer risk stratified by hormone receptor status

Collaborators

1. Dr. Omar Abdel-Rahman
1. Dr. Winson Cheung
2. Dr. Patricia Tang

Related Publications

• Evaluating Family History Links between Breast Cancer and Prostate Cancer Among PLCO Trial Participants.
  Abdel-Rahman O
  Clin Breast Cancer. 2020 Aug; Volume 20 (Issue 4): Pages 300-306 PUBMED
• Subtype-specific risk factors for postmenopausal breast cancer: findings from the PLCO trial.
  Abdel-Rahman O, Tang PA, Cheung WY
  Clin Transl Oncol. 2020 Mar 10 PUBMED